Amarin : AMRN

All Amarin Articles

63 Articles

Jon C. Ogg | Nov 8, 2013 at 8:45 AM EST

Top Analyst Upgrades and Downgrades: Amarin, Deere, First Solar and More

Jon OggThis week should be the end of the major earnings flood. With markets so close to highs, investors and…

Jon C. Ogg | Oct 17, 2013 at 9:45 AM EDT

Amarin Implosion: The Future Went from Promising to Doubtful

ThinkstockBiotech is a sector where investors know they are entering a high-stakes game of big risk and big reward. That…

Jon C. Ogg | Oct 17, 2013 at 8:45 AM EDT

Top Analyst Upgrades and Downgrades: Amarin, IBM, Salesforce.com, SolarCity and More

Jon OggEarnings season has started as Washington, D.C., seems to have figured a way out of its shenanigans again. Now…

Jon C. Ogg | Sep 30, 2013 at 10:35 AM EDT

Five FDA Approvals and Reviews at Risk Under a Government Shutdown

via Wikimedia CommonsIt looks like Congress and the president still cannot figure out how to play well with each other,…

Jon C. Ogg | Jul 1, 2013 at 8:20 AM EDT

Top Biotech Stocks to Buy and Stocks to Short From PropThink

ThinkstockThe world of biotech investing is always a difficult one. Often a binary event, such as a Food and Drug…

Jon C. Ogg | Jan 4, 2013 at 5:42 AM EST

12 Stocks Expected to Rise by 50% to 100% (or More) in 2013 (AMRN, CRZO, CNDO, EMKR, ETRM, EXAS, GALE, MX, OEDV, REGI, SPWR, SGYP)

It may seem hard to believe, but some stocks are expected to rise by 50%, 100%, or even more over…

Paul Ausick | Dec 7, 2012 at 4:04 PM EST

24/7 Wall St. Closing Bell — December 7, 2012: Markets Wobble to Mixed Close (TCK, MCD, SYT, AET, MPEL, HWD, PANW, SWHC, WGO, UEC, SMRT, SCHL, FGP, CMVT, AMRN, GRPN, F)

U.S. equity markets opened higher this morning following a poor growth forecast from Europe and a better-than-expected report on U.S.…

Paul Ausick | Dec 7, 2012 at 9:21 AM EST

Amarin Takes on More Debt, Shares Suffer

ThinkstockBiopharmaceutical company Amarin Corp. PLC (NASDAQ: AMRN) announced after markets closed last night that it has received $100 million in…

Jon C. Ogg | Nov 27, 2012 at 8:28 AM EST

Top Analyst Upgrades and Downgrades (AMRN, BSX, BRCD, CVC, CFNL, CROX, FINL, FL, GMO, HMA, LAZ, NOV, OTEX, PCG, RH, SHOO, VPHM, YELP)

Jon OggThese are some of the top analyst upgrades, downgrades and initiations seen in Wall St. research calls this Tuesday.…

Jon C. Ogg | Nov 8, 2012 at 5:35 PM EST

Hot After-Hours Stocks on the Move (MDRX, AMRN, GRPN, KYAK, PCLN, EXPE,OWW, TRIP, LGF, MCP, PEGA, SPRD, ZIP)

ThinkstockWe are tracking many key movers in the after-hours trading this Thursday. Most are earnings but some are not. Allscripts Healthcare…

Jon C. Ogg | Oct 10, 2012 at 2:40 PM EDT

Amarin Becomes A January 2013 Story on FDA Uncertainty

Amarin Corporation plc (NASDAQ: AMRN) is not exactly having a good day considering that its fish oil based drug for lowering…

247sam | Jul 27, 2012 at 11:23 AM EDT

Amarin Shares Fall Despite Regulatory OK

Usually, shares of drug makers soar following the announcement that the Foood and Drug Administration approved a drug. Amarin Corp.…

Jon C. Ogg | Jul 16, 2012 at 10:43 AM EDT

Looking for the Next Biotech Buyout After Two Drug and Biotech Deals

What usually happens when you get two mergers announced in drugs and biotech in the same day? Investors begin to…

Jon C. Ogg | Jul 10, 2012 at 7:35 AM EDT

Finding the Next Biotech M&A Targets (HGSI, GSK, AMLN, BMY, VRTX, CELG, CBST, AMRN, DNDN, BMRN, VVUS, ARNA, PCYC, VICL, MDGN, AFFX, THRX, RIGL)

More biotech mergers are on the way! That is the verdict of Wall St. There may be patent protection risks…

Jon C. Ogg | Jul 2, 2012 at 2:42 PM EDT

Which Biotechs Could Be Next M&A Targets (AMLN, BMY, VRTX, CELG, CBST, AMRN, BMRN, VVUS, ARNA, PCYC, AFFX, THRX, RIGL, HGSI, GSK, DNDN)

The freshly announced multibillion biotech buyout of Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) for more than $5 billion in equity value…

1 2 3 4 5

Amarin : AMRN

All Amarin Articles

Top Analyst Upgrades and Downgrades: Amarin, Deere, First Solar and More

Amarin Implosion: The Future Went from Promising to Doubtful

Top Analyst Upgrades and Downgrades: Amarin, IBM, Salesforce.com, SolarCity and More

Five FDA Approvals and Reviews at Risk Under a Government Shutdown

Top Biotech Stocks to Buy and Stocks to Short From PropThink

12 Stocks Expected to Rise by 50% to 100% (or More) in 2013 (AMRN, CRZO, CNDO, EMKR, ETRM, EXAS, GALE, MX, OEDV, REGI, SPWR, SGYP)

24/7 Wall St. Closing Bell — December 7, 2012: Markets Wobble to Mixed Close (TCK, MCD, SYT, AET, MPEL, HWD, PANW, SWHC, WGO, UEC, SMRT, SCHL, FGP, CMVT, AMRN, GRPN, F)

Amarin Takes on More Debt, Shares Suffer

Top Analyst Upgrades and Downgrades (AMRN, BSX, BRCD, CVC, CFNL, CROX, FINL, FL, GMO, HMA, LAZ, NOV, OTEX, PCG, RH, SHOO, VPHM, YELP)

Hot After-Hours Stocks on the Move (MDRX, AMRN, GRPN, KYAK, PCLN, EXPE,OWW, TRIP, LGF, MCP, PEGA, SPRD, ZIP)

Amarin Becomes A January 2013 Story on FDA Uncertainty

Amarin Shares Fall Despite Regulatory OK

Looking for the Next Biotech Buyout After Two Drug and Biotech Deals

Finding the Next Biotech M&A Targets (HGSI, GSK, AMLN, BMY, VRTX, CELG, CBST, AMRN, DNDN, BMRN, VVUS, ARNA, PCYC, VICL, MDGN, AFFX, THRX, RIGL)

Which Biotechs Could Be Next M&A Targets (AMLN, BMY, VRTX, CELG, CBST, AMRN, BMRN, VVUS, ARNA, PCYC, AFFX, THRX, RIGL, HGSI, GSK, DNDN)

MISL Investors: Watch the FY27 Budget Bill Before the Next Rally

Fed’s Rate Freeze Could Sting for Social Security Recipients

‘Convert $100,000 a Year to Get Them to the Top of the 22%’: The Roth Plan for a Couple With $2.3M in 401(k)s

Fed’s Rate Freeze Could Sting for Social Security Recipients

'Convert $100,000 a Year to Get Them to the Top of the 22%': The Roth Plan for a Couple With $2.3M in 401(k)s

MISL Investors: Watch the FY27 Budget Bill Before the Next Rally

Fed’s Rate Freeze Could Sting for Social Security Recipients

Amarin : AMRN

All Amarin Articles

Top Analyst Upgrades and Downgrades: Amarin, Deere, First Solar and More

Amarin Implosion: The Future Went from Promising to Doubtful

Top Analyst Upgrades and Downgrades: Amarin, IBM, Salesforce.com, SolarCity and More

Five FDA Approvals and Reviews at Risk Under a Government Shutdown

Top Biotech Stocks to Buy and Stocks to Short From PropThink

12 Stocks Expected to Rise by 50% to 100% (or More) in 2013 (AMRN, CRZO, CNDO, EMKR, ETRM, EXAS, GALE, MX, OEDV, REGI, SPWR, SGYP)

24/7 Wall St. Closing Bell — December 7, 2012: Markets Wobble to Mixed Close (TCK, MCD, SYT, AET, MPEL, HWD, PANW, SWHC, WGO, UEC, SMRT, SCHL, FGP, CMVT, AMRN, GRPN, F)

Amarin Takes on More Debt, Shares Suffer

Top Analyst Upgrades and Downgrades (AMRN, BSX, BRCD, CVC, CFNL, CROX, FINL, FL, GMO, HMA, LAZ, NOV, OTEX, PCG, RH, SHOO, VPHM, YELP)

Hot After-Hours Stocks on the Move (MDRX, AMRN, GRPN, KYAK, PCLN, EXPE,OWW, TRIP, LGF, MCP, PEGA, SPRD, ZIP)

Amarin Becomes A January 2013 Story on FDA Uncertainty

Amarin Shares Fall Despite Regulatory OK

Looking for the Next Biotech Buyout After Two Drug and Biotech Deals

Finding the Next Biotech M&A Targets (HGSI, GSK, AMLN, BMY, VRTX, CELG, CBST, AMRN, DNDN, BMRN, VVUS, ARNA, PCYC, VICL, MDGN, AFFX, THRX, RIGL)

Which Biotechs Could Be Next M&A Targets (AMLN, BMY, VRTX, CELG, CBST, AMRN, BMRN, VVUS, ARNA, PCYC, AFFX, THRX, RIGL, HGSI, GSK, DNDN)

MISL Investors: Watch the FY27 Budget Bill Before the Next Rally

Fed’s Rate Freeze Could Sting for Social Security Recipients

‘Convert $100,000 a Year to Get Them to the Top of the 22%’: The Roth Plan for a Couple With $2.3M in 401(k)s

Featured Reads

Fed’s Rate Freeze Could Sting for Social Security Recipients

'Convert $100,000 a Year to Get Them to the Top of the 22%': The Roth Plan for a Couple With $2.3M in 401(k)s